Fresenius Medical Care (FME) Earnings Beat Estimates with a 22% Rise in 4Q Operating Income

Fresenius Medical Care & on Smartkarma

Fresenius Medical Care (FME GR) recently received improved guidance from top independent analyst Tina Banerjee on Smartkarma, an investment research network. In her latest report, Banerjee notes that the company has reported accelerated organic revenue growth of 6% YoY in the second quarter of 2023. This is a strong improvement from previous quarters and is a result of the company’s successful execution of its turnaround plan. The plan has led to improved operating profit, although it is expected to remain flat or slightly decline in 2023.

Banerjee also highlights that Fresenius Medical Care & (FME GR) has achieved visible productivity improvements in its care delivery segment, with a Q2 margin at the lower end of the 2025 target margin band of 10-14%. This is a positive sign for the company’s future performance. Additionally, the company has revised its 2023 operating income target to remain flat or decline by up to a low-single-digit percentage, a significant improvement from its previous target of remaining flat or declining by up to a high-single-digit percentage. This news has been well received by investors and shows that Fresenius Medical Care is on track with its turnaround plan.

A look at Fresenius Medical Care & Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Fresenius Medical Care AG & Co. KGaA is a company that provides services and products for patients who need kidney dialysis. They also offer other medical services such as laboratory testing and home therapy. The company operates globally and is known for their high scores in different areas.

According to the Smartkarma Smart Scores, Fresenius Medical Care scores well in terms of value, dividend, growth, and momentum. This means that the company is financially stable, pays out dividends to its shareholders, has potential for growth, and has a good track record in the market. However, in terms of resilience, the company only received a score of 2 out of 5. This suggests that while Fresenius Medical Care is performing well overall, there may be some risks or challenges that could affect its long-term outlook. Overall, with its high scores in most areas, Fresenius Medical Care seems to have a positive long-term outlook.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma